Stereotaxis Genesis Robotic System Achieves Regulatory Approval in China

STXS 11.25.2024

SERA-AI Powered Highlights
Full Press ReleaseSEC FilingsOur STXS Tweets

About Gravity Analytica

Recent News

  • 01.14.2025 - Oulu University Hospital Enhances Leadership in Arrhythmia Care with Advanced Genesis Robotic Technology
  • 01.06.2025 - Patricia Williams
  • 12.09.2024 - Magbot Robotic Magnetic Navigation Ablation Catheter Approved by China’s NMPA

Recent Filings

  • 01.02.2025 - 4 Statement of changes in beneficial ownership of securities
PDF Version

ST. LOUISandSHANGHAI,Nov. 25, 2024(GLOBE NEWSWIRE) --Stereotaxis(NYSE: STXS) and Shanghai MicroPort EP Medtech Co., Ltd. (688351.SH, “MicroPort EP”), today announced regulatory approval of theGenesis RMN®Systemby China’sNational Medical Products Administration(NMPA).

This approval is a significant milestone, making available the latest advances in minimally-invasive robotic technology to physicians and patients inChina. MicroPort EP is initiating full commercial launch of Genesis through its existing sales teams focused on the electrophysiology community. Approval of Genesis is a key element in a broader collaboration betweenStereotaxisand MicroPort EP which entails the development, integration and commercialization of Stereotaxis’ robotic system, robotically-navigated catheters, and MicroPort EP’s ColumbusTM 3D mapping system. MicroPort EP is one of China’s leading medical device companies with a portfolio of cardiovascular medical devices designed to diagnose and treat arrythmias.Stereotaxisand MicroPort EP previously announced their collaboration inAugust 2021.

“We are proud to partner withStereotaxisto bring the benefits of the Genesis system to China,” said Dr.Yiyong Sun, President of MicroPort EP. “We look forward to launching this significant technology and continuing our partnership to provide China’s electrophysiology community with the most advanced innovations.”

"We are delighted to receive NMPA clearance for the Genesis System inChina," saidDavid Fischel,StereotaxisChairman and CEO. "This approval represents another key milestone as we establish the foundations for significant growth across key focus geographies. Our investment to advance the substantial innovations underscores our commitment to pioneering the frontiers of medical technology to improve the lives of patients with cardiovascular disease around the world.”

Genesis is the latest innovation in Robotic Magnetic Navigation technology. Robotic Magnetic Navigation introduces the benefits of robotic precision and safety to minimally-invasive endovascular procedures. The Genesis RMN System has FDA clearance and is CE marked, with systems acrossthe United StatesandEuropehaving been used to treat thousands of patients.

AboutStereotaxisStereotaxis(NYSE: STXS) is a pioneer and global leader in innovative surgical robotics for minimally invasive endovascular intervention. Its mission is the discovery, development and delivery of robotic systems, instruments, and information solutions for the interventional laboratory. These innovations help physicians provide unsurpassed patient care with robotic precision and safety, expand access to minimally invasive therapy, and enhance the productivity, connectivity, and intelligence in the operating room.Stereotaxistechnology has been used to treat over 150,000 patients acrossthe United States,Europe,Asia, and elsewhere. For more information, please visitwww.Stereotaxis.com.

This press release includes statements that may constitute "forward-looking" statements, usually containing the words "believe”, "estimate”, "project”, "expect" or similar expressions. Forward-looking statements inherently involve risks and uncertainties that could cause actual results to differ materially. Factors that would cause or contribute to such differences include, but are not limited to, the Company's ability to manage expenses at sustainable levels, acceptance of the Company's products in the marketplace, the effect of global economic conditions on the ability and willingness of customers to purchase its technology, competitive factors, changes resulting from healthcare policy, dependence upon third-party vendors, timing of regulatory approvals, the impact of pandemics or other disasters, and statements relating to our recent acquisition of APT, including any benefits expected from the acquisition, and other risks discussed in the Company's periodic and other filings with theSecurities and Exchange Commission. By making these forward-looking statements, the Company undertakes no obligation to update these statements for revisions or changes after the date of this release. There can be no assurance that the Company will recognize revenue related to its purchase orders and other commitments because some of these purchase orders and other commitments are subject to contingencies that are outside of the Company's control and may be revised, modified, delayed, or canceled.

Stereotaxis Contacts:David L. FischelChairman and Chief Executive Officer

Kimberly PeeryChief Financial Officer

314-678-6100Investors@Stereotaxis.com

Primary Logo

Source: Stereotaxis, Inc.

Please be aware that the following content has been generated by an AI system and may contain errors, inconsistencies, or outdated information. It is provided as-is without any warranties or guarantees of accuracy. We strongly recommend using this content as a starting point for further research and consultation with relevant experts or authorities. We disclaim any liability for damages or losses resulting from the use or reliance on this content.Please note that this is a beta version of the Gravity Analytica LLC’s AI Service which isstill undergoing final testing before its official release. Theplatform, its software and all content found on it are provided on an“as is” and “as available” basis. Gravity Analytica LLC does not give any warranties,whether express or implied, as to the suitability or usability of thisservice, webpage, or its software or any of its content.Should you encounter any bugs, glitches, lack of functionality orother problems on the website, please let us know immediately so wecan rectify these accordingly. Your help in this regard is greatlyappreciated! You can write to us at this addressteam@gravityanalytica.com